BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35773668)

  • 1. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.
    Tong T; Qin X; Jiang Y; Guo H; Wang X; Li Y; Xie F; Lu H; Zhai P; Ma H; Zhang J
    BMC Med; 2022 Jul; 20(1):231. PubMed ID: 35773668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
    J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5.
    Jiang Y; Guo H; Tong T; Xie F; Qin X; Wang X; Chen W; Zhang J
    Mol Ther; 2022 Jan; 30(1):448-467. PubMed ID: 34111560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
    Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
    Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
    Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
    J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
    Cui L; Lu Y; Zheng J; Guo B; Zhao X
    J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
    Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
    Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 13. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system.
    Ogawa T; Ono K; Ryumon S; Kawai H; Nakamura T; Umemori K; Yoshida K; Kanemoto H; Obata K; Yoshioka N; Okui T; Okamoto K; Nagatsuka H; Ibaragi S
    Head Neck; 2024 Mar; 46(3):636-650. PubMed ID: 38164660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
    Yassin-Kassab A; Chatterjee S; Khan N; Wang N; Sandulache VC; Huang EH; Burns TF; Duvvuri U
    BMC Cancer; 2024 Feb; 24(1):233. PubMed ID: 38373988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma.
    Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X
    PeerJ; 2024; 12():e17296. PubMed ID: 38756442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
    Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
    Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
    Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
    Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.